ADEOYE OLUKOTUN, MD, MPH - Corporate Board Profile

ARROWHEAD PHARMACEUTICALS, INC.

Filing Date	Source Excerpt
2022-01-26	Dr. Olukotun is a Mayo Clinic trained cardiologist who has served as Chief Executive Officer of CR Strategies, LLC, which consults on clinical trial design and FDA strategy for pharmaceutical development , since 2001. Dr. Olukotun currently serves on the board of directors of Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a clinical-stage biopharmaceuticals company. He served as CEO of Epigen Pharmaceuticals, Inc., a discovery phase biotechnology company, from 2014 to 2017, and Vice Board Chair of CardioVax, Inc., a clinical-stage biopharmaceutical company, from 2012 to 2016. He spent the first 20 years of his career in roles of increasing responsibility in clinical development, including multiple product approvals, at Pfizer, Bristol-Myers Squibb, and Mallinckrodt. He has over 35 years of experience in the pharmaceutical industry and has been instrumental in the approval and success of numerous cardiology and metabolic medicines, including the first daily beta blocker and the first approved ACE inhibitor, among others. Dr. Olukotun serves on the Science Committee (Co-Chair), Audit Committee, Compensation Committee and Nominating Committee. His total compensation for 2021 was $765,570.
2023-01-30	Adeoye Olukotun, MD, MPH Independent Director Age: 78 Director since: 2020 Serves on: •Science Committee (Co-Chair) •Nomination Committee The following table sets forth the total compensation paid to our non-employee directors in fiscal 2022. Adeoye Olukotun $80,000 Fee Earned or Paid in Cash, $377,280 Stock Awards, Total $457,280.
2024-01-26	Adeoye Olukotun, MD, MPH Independent Director Age: 79 Director since: 2020 Serves on: • Science Committee (Co-Chair) • Nomination Committee Other Public Company Boards: • Tonix Pharmaceuticals Holding Corp. Dr. Olukotun is a Mayo Clinic trained cardiologist who has served as Chief Executive Officer of CR Strategies, LLC, which consults on clinical trial design and FDA strategy for pharmaceutical development , since 2001. Dr. Olukotun currently serves on the board of directors of Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a clinical-stage biopharmaceuticals company. He served as CEO of Epigen Pharmaceuticals, Inc., a discovery phase biotechnology company, from 2014 to 2017, and Vice Board Chair of CardioVax, Inc., a clinical-stage biopharmaceutical company, from 2012 to 2016. He spent the first 20 years of his career in roles of increasing responsibility in clinical development, including multiple product approvals, at Pfizer, Bristol-Myers Squibb, and Mallinckrodt. He has over 35 years of experience in the pharmaceutical industry and has been instrumental in the approval and success of numerous cardiology and metabolic medicines, including the first daily beta blocker and the first approved ACE inhibitor, among others. Dr. Olukotun received his Medical Doctor degree from the Albert Einstein College of Medicine in New York, and a Masters in Public Health from Harvard University School of Public Health. Dr. Olukotun’s qualifications to serve on the Board include his extensive background in biopharmaceutical development, particularly in the cardiometabolic field, his scientific and public health expertise, and his board and executive leadership experience. Total compensation paid to our non-employee directors in fiscal 2023: $459,602.
2025-01-29	Adeoye Olukotun, MD, MPH Independent Director Age: 80 Serves on: • Science Committee (Co-Chair) • Nomination Committee Total compensation paid to our non-employee directors in fiscal 2024: $460,833.